Clinic for General and Visceral Surgery, Hospital Barmherzige Brüder Regensburg, Germany.
Clinic for General and Visceral Surgery, Hospital Barmherzige Brüder Regensburg, Germany.
Clin Colorectal Cancer. 2024 Dec;23(4):309-317. doi: 10.1016/j.clcc.2024.05.007. Epub 2024 May 21.
The peritoneal metastasized colorectal cancer (pmCRC) represents a serious health problem worldwide with a special emphasis in the developed countries. Several guidelines recognize the role of multimodal therapy consisting of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of pmCRC. New data suggests that some other factors, eg, tumor biology, immune profile, neoadjuvant chemotherapy may play a predictive role for the oncological outcome of these patients.
腹膜转移结直肠癌(pmCRC)是一个全球性的严重健康问题,在发达国家尤为突出。多项指南都承认细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)的多模态治疗方案在 pmCRC 治疗中的作用。新的数据表明,其他一些因素,如肿瘤生物学、免疫特征、新辅助化疗等可能对这些患者的肿瘤学结局具有预测作用。